

Nerve conduction studies

Adjudication Guideline

Rule Category:
Billing

Ref: No:
2016-BR-0004

Version Control:
Version No. 4.0

Effective Date:
22/09/2016

Revision Date:
17/04/2026

Approved by:
Daman

Responsible:
Medical Standards
& Governance

**Related Adjudication
Guidelines:**
NA

Table of Contents

1.	Abstract	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope	3
3.	Adjudication Policy.....	4
3.1	Eligibility / Coverage Criteria.....	4
3.2	Requirements for Coverage	6
3.3	Non-Coverage.....	6
3.4	Payment and Coding Rules	7
4.	Denial Codes.....	7
5.	Appendices	8
5.1	References	8
5.2	Revision History	8

1. Abstract

1.1 For Members

Nerve conduction studies are performed to assess the integrity and diagnose diseases of the Peripheral nervous system. Pathological findings include conduction slowing, conduction block, no response, and/or low amplitude response.

1.2 For Medical Professionals

This adjudication rule aims to specify coverage details for nerve conduction studies; Nerve conduction study results can assess the degree of demyelination and axon loss in the segments of the nerve studied.

Daman covers nerve conduction studies where medically necessary.

- To establish the diagnosis and prognosis of traumatic nerve lesions and
- monitoring of neuromuscular junction disorders (e.g., myasthenia gravis).
- To establish the diagnosis of muscle disorders (e.g., myopathy).
- To diagnose generalized neuropathies and symptom centric complaints.
- Localization of compressive lesions (e.g., carpal tunnel syndrome).

2. Scope

This adjudication rule highlights the medical necessity, coding and coverage rules for Nerve Conduction Studies (NCS) as per policy terms and conditions for all health insurance plans administered by Daman.

Nerve Conduction Studies (NCS) is performed to assess the integrity and diagnose diseases of the Peripheral nervous system. Pathological findings include conduction slowing, conduction block, no response, and/or low amplitude response. NCS results can assess the degree of demyelination and axon loss in the segments of the nerve studied.

Motor NCS: Performed by applying electrical signal to various points along the course of a motor nerve while recording the electrical response from an appropriate muscle. Response parameters include amplitude, latency, configuration, and motor conduction velocity.

Sensory NCS: Performed by applying electrical signal stimulation near a sensory nerve and recording the response from a distant site along the nerve. Response parameters include amplitude, latency, configuration, and motor conduction velocity.

Mixed NCS: Performed by applying electrical stimulation near a nerve containing both motor and sensory fibres (a mixed nerve) and recording from a different location along that nerve that also contains both motor and sensory nerve fibres.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Medical Indication:

- Diagnosis and prognosis of traumatic nerve lesions (e.g., spinal cord injury, trauma to nerves).
- Diagnosis and monitoring of neuromuscular junction disorders (e.g., myasthenia gravis, myasthenic syndrome).
- Diagnosis of muscle disorders (e.g., myositis, myopathy). • Diagnosis or confirmation of suspected generalized neuropathies (including uremic, metabolic, or immune) (e.g., amyotrophic lateral sclerosis, GuillainBarré Syndrome, muscular dystrophy, post-polio syndrome).
- Differential diagnosis of physical examination findings of sensory loss, weakness and/or muscle atrophy with no known etiology (e.g., diabetes, hypothyroidism, lupus, rheumatoid arthritis, etc.).
- Differential diagnosis of symptom-based complaints e.g., pain in limb or joint, weakness, fatigue, cramps, twitching (fasciculations), disturbance in skin sensation or paraesthesia (numbness or tingling) provided the clinical assessment supports the need for a study.
- Localization of focal neuropathies or compressive lesions (e.g., Bell’s palsy of the facial nerve, carpal tunnel syndrome, cubital tunnel syndrome, tarsal tunnel syndrome, nerve root compression, neuritis, motor neuropathy, mononeuropathy, radiculopathy, unexplained peripheral neuropathy with pain of a neuropathic pattern).

Table 1: Reasonable Maximum Number of Nerve Conduction Studies

Indications	Nerve conduction studies (Total nerves studies, 95907-95913)
Carpal tunnel (unilateral)	7
Carpal tunnel (bilateral)	10
Radiculopathy	7
Mononeuropathy	8

Polyneuropathy/ Mononeuropathy multiplex	10
Myopathy	4
Motor Neuropathy (e.g., ALS)	6
Plexopathy	12
Neuromuscular junction	4
Tarsal tunnel syndrome (unilateral)	8
Tarsal tunnel syndrome (bilateral)	11
Weakness, Fatigue, Cramps, or Twitching (focal)	7
Weakness, Fatigue, Cramps, or Twitching (general)	8
Pain, Numbness, or Tingling (unilateral)	9
Pain, Numbness, or Tingling (bilateral)	12

Table 2: Eligible Health professionals

Eligible Ordering Clinician
Internal medicine subspecialties of Neurology, Endocrinology, Rheumatology
Paediatrics subspecialties of Neurology, Endocrinology, Rheumatology
Anaesthesiology and Critical Care Medicine
Pain medicine
Physical Medicine and Rehabilitation
Orthopaedics
Neurosurgery and Neurology

Table 3: CPT codes

CPT code	Code description
95905	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report
95907	Nerve conduction studies; 1-2 studies
95908	Nerve conduction studies; 3-4 studies
95909	Nerve conduction studies; 5-6 studies
95910	Nerve conduction studies; 7-8 studies
95911	Nerve conduction studies; 9-10 studies
95912	Nerve conduction studies; 11-12 studies
95913	Nerve conduction studies; 13 or more studies

3.2 Requirements for Coverage

- ICD and CPT codes must be coded to the highest level of specificity.
- Failure to submit, upon request or when requesting an informal review, a clinical history indication the need for testing will result in rejection of claim.

3.3 Non-Coverage

- Nerve conduction studies are not covered for visitor plan.
- Will not be covered by Daman (for any plan) if it is not supported by a medically justified indication/diagnosis.
- For screening evaluation.

3.4 Payment and Coding Rules

Please apply regulator payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

- Table 1: Reasonable Maximum Number of Nerve Conduction Studies (scope)
- Table 2: Eligible Health professionals
- Table 3: CPT Codes
- NCS reports should document the nerves evaluated, the distance between the stimulation and recording sites, the conduction velocity, latency, and amplitude,
- The CPT descriptor language, codes 95907-95913 describe one or more nerve conduction studies. For the purposes of coding, a single conduction study is defined as a sensory conduction test, a motor conduction test with or without an F-wave test, or an H-reflex test. Each type of nerve conduction study is counted only once when multiple sites on the same nerve are stimulated or recorded. The number of these separate tests should be added to determine which code to use, (for ICD 10 categorization and recommended studies.). It is inappropriate to count more than one unit for “inching” or studying the same nerve by moving the stimulating electrode closer to the recording electrode.
- Minimum retesting time interval: Repeat testing should only be performed when medically indicated, based on documented clinical changes, follow-up needs, or reassessment of the patient’s condition.

4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
MNEC-005	Service /supply may be appropriate, but too frequent
CODE-010	Activity / diagnosis inconsistency with clinician speciality
PRCE-002	Payment is included in the allowance for another service

5. Appendices

5.1 References

- <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57307>
- <https://www.aanem.org/docs/default-source/documents/recommended-policy-2023.pdf>
- https://www.anthem.com/medpolicies/abc/active/gl_pw_a057015.html
- <https://www.ncbi.nlm.nih.gov/books/NBK611987/>
- <https://www.aanem.org/docs/default-source/documents/aanem/advocacy/model-policy-for-nerve-conduction-studies-and-needle-electrom>
- <https://practicalneurology.com/diseases-diagnoses/neuromuscular/emg-and-nerve-conduction-studies-in-clinical-practice/30863/>
- <https://www.racgp.org.au/getattachment/629d74e6-4c1f-4690-b368-d1b8606ffc8f/Nerve-conduction-studies.aspx>

5.2 Revision History

Date	Change(s)
14/03/2023	Release of V1.0 Creation of Adjudication Guideline
09/05/2023	Release of V2.0 Updated Reasonable Maximum Number of Nerve Conduction Studies New CPT 2018 codes added
30/12/2024	Release of V3.0 General Content and Template update
17/04/2026	Release of V4.0 Clinician and Payment and coding updated General Content and Template update

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed. Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website. This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties. This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.